Cardiff Oncology, Inc. ( (CRDF) ) has released its Q3 earnings. Here is a breakdown of the information Cardiff Oncology, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cardiff Oncology, Inc. is a clinical-stage biotechnology company based in San Diego, California, focusing on developing novel cancer therapies through Polo-like Kinase 1 inhibition. The latest earnings report for the quarter ending September 30, 2025, highlights a decrease in revenues and an increase in net losses compared to the previous year. Key financial metrics include a net loss of $11.3 million for the quarter and $38.7 million for the nine months, with research and development expenses rising due to ongoing clinical trials. The company continues to focus on its lead drug candidate, onvansertib, which is being tested in various cancer indications. Despite the financial challenges, Cardiff Oncology remains committed to advancing its clinical programs and exploring strategic opportunities to enhance its pipeline.